Healthequity (NASDAQ:HQY) had its target price upped by Chardan Capital from $58.00 to $62.00 in a research report issued on Wednesday. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 27.86% from the company’s previous close.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub upgraded shares of Healthequity from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. Cantor Fitzgerald restated a “buy” rating and issued a $56.00 target price on shares of Healthequity in a report on Monday, September 25th. Robert W. Baird restated a “hold” rating on shares of Healthequity in a report on Thursday, September 21st. Finally, Oppenheimer restated a “buy” rating and issued a $61.00 target price on shares of Healthequity in a report on Wednesday, September 6th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $58.33.
Healthequity (NASDAQ HQY) opened at $48.49 on Wednesday. The company has a market cap of $2,955.48, a P/E ratio of 77.56, a price-to-earnings-growth ratio of 2.14 and a beta of 1.74. Healthequity has a one year low of $37.62 and a one year high of $55.31.
In other Healthequity news, Director Frank Medici sold 316,644 shares of the firm’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $51.96, for a total transaction of $16,452,822.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Neeleman sold 8,500 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $45.24, for a total value of $384,540.00. Following the transaction, the insider now directly owns 1,000 shares of the company’s stock, valued at approximately $45,240. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,733,212 shares of company stock worth $90,635,651. 19.00% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in HQY. Zions Bancorporation purchased a new position in Healthequity during the third quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Healthequity by 105.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after buying an additional 1,308 shares during the period. Riverhead Capital Management LLC raised its position in shares of Healthequity by 75.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock worth $131,000 after purchasing an additional 1,129 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Healthequity by 7.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock worth $134,000 after purchasing an additional 191 shares during the last quarter. Finally, Fortaleza Asset Management Inc. purchased a new position in shares of Healthequity in the 2nd quarter worth about $138,000. 98.60% of the stock is owned by institutional investors and hedge funds.
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity Inc and related companies with MarketBeat.com's FREE daily email newsletter.